Furthermore, for uveal melanoma (UVM) and TGCT patients, the SETDB1 expression levels in cancers at advanced clinicopathological stages were significantly lower than those in tumors at early stages, implying that decreased SETDB1 expression may indicate the tumor progression in these patients (Figures 6(r) and 6(s)). This evidence concerns the gene SETDB1 and cancer.